Search

Displaying results 2911 - 2920 of 10000 in total
  1. Drug

    Danaparoid

    go.drugbank.com/drugs/DB06754
    ApprovedWithdrawn

    Danaparoid sodium is the common salt form in therapeutic preparations and is typically administered subcutaneously. … While it was initially approved by the FDA as Orgaran™, danaparoid was withdrawn by Organon International on August 14, 2002, due to a shortage in drug substance by the manufacturer.

  2. Drug

    Sarafloxacin

    go.drugbank.com/drugs/DB11491
    ApprovedVet approvedWithdrawn

    Sarafloxacin is a quinolone antibiotic drug, which was discontinued by its manufacturer, Abbott Laboratories, before receiving approval for use in the US or Canada.

  3. Drug

    Narsoplimab

    go.drugbank.com/drugs/DB16418
    ApprovedInvestigational

    [A241030] Evidence increasingly points to a role for the complement system in TMA. … [A241045, A241050] Approved by the FDA on December 24, 2025, narsoplimab-wuug is indicated for the treatment of hematopoietic stem cell transplant–associated thrombotic microangiopathy (TA-TMA) in adults

    Synonyms: MANNAN-BINDING LECTIN SERINE PROTEASE 2 (MANNOSE-BINDING PROTEIN-ASSOCIATED SERINE PROTEASE 2, EC=3.4.21.104) HUMAN MONOCLONAL ANTIBODY .GAMMA.4 HEAVY CHAIN (1-445) (HOMO SAPIENS VH (IGHV2-26*01 (94%) (IGHD)-I
  4. Drug

    Levobetaxolol

    go.drugbank.com/drugs/DB09351
    Approved

    Levobetaxolol is a beta-blocker used to lower the pressure in the eye to treat conditions such as glaucoma. … It was marketed as a 0.5% ophthalmic solution of levobetaxolol hydrochloride under the trade name Betaxon but has been discontinued.

  5. Drug

    Iptacopan

    go.drugbank.com/drugs/DB16200
    ApprovedInvestigational

    [A262581] On December 6th, 2023, Iptacopan under the brand name Fabhalta was approved by the FDA for the treatment of adults with PNH. … Iptacopan is a small-molecule factor B inhibitor previously investigated as a potential treatment for the rare blood disease paroxysmal nocturnal hemoglobinuria (PNH) by inhibiting the complement factor

    Categories: Compounds used in a research, industrial, or household setting
  6. Drug

    Aficamten

    go.drugbank.com/drugs/DB18490
    ApprovedInvestigational

    [L54788] Approved by the FDA on December 19, 2025, aficamten is indicated for the treatment of adults with symptomatic obstructive hypertrophic cardiomyopathy (oHCM) to improve functional capacity and … Aficamten is a cardiac myosin inhibitor.

    Synonyms: (R)-N-(5-(5-ethyl-1,2,4-oxadiazol-3-yl)-2,3-dihydro-1H-inden-1-yl)- 1-methyl-1H-pyrazole-4-carboxamide, (R)-N-(5-(5-ethyl-1,2,4-oxadiazol-3-yl)-2,3-dihydro-1H-inden-1-yl)-1-methyl-1H-pyrazole-4-carboxamide
  7. Drug

    Gadoquatrane

    go.drugbank.com/drugs/DB33282
    Approved

    [L63930] Bayer announced FDA approval of gadoquatrane on June 15, 2026, for use with MRI in adult and pediatric patients, including term neonates, to detect and visualize lesions with abnormal vascularity … [L63814,L63930] Reduced gadolinium exposure is important for patients requiring repeated lifetime imaging - e.g. for multiple sclerosis, spinal conditions, or cancer surveillance - given clinical guidance

  8. Drug

    Ferrous bisglycinate

    go.drugbank.com/drugs/DB11210
    Approved

    It is found in foods for food enrichment or in supplements for the treatment of iron deficiency or iron deficiency anemia. … Ferrous bisglycinate is a chelate that is used as a source of dietary iron.

    Mixtures: vitaMedMD Rx Plus
  9. Drug

    VL-2397

    go.drugbank.com/drugs/DB17796
    Investigational

    Synonyms: Cyclo(l-asparaginyl-l-leucyl-d-phenylalanyl-n5-acetyl-n5-hydroxy-l-ornithyl-n5-acetyl-n5-hydroxy-l-ornithyl-n5-acetyl-n5-hydroxy-l-ornithyl), aluminum salt (1:1), Cyclo(-asn-leu-d-phe-al((n5-acetyl-n5-hydroxy-orn)-(n5-acetyl-n5-hydroxy-orn)-(n5-hydroxy-orn))-) . al(iii)
  10. Drug

    Porfimer sodium

    go.drugbank.com/drugs/DB00707
    ApprovedInvestigational

    It is the first drug to be approved in the use of photodynamic therapy in the United States. … It is used in photodynamic therapy (hematoporphyrin photoradiation); to treat malignant lesions with visible light and experimentally as an antiviral agent.

    Categories: Sensitizers Used in Photodynamic/radiation Therapy, Photosensitizing Agents for PhototherapyInternational brands: Photofrin II